Log in
NASDAQ:ESPR

Esperion Therapeutics Stock Forecast, Price & News

$37.52
+1.47 (+4.08 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$35.60
Now: $37.52
$37.70
50-Day Range
$31.18
MA: $35.79
$39.52
52-Week Range
$24.82
Now: $37.52
$76.98
Volume322,037 shs
Average Volume729,680 shs
Market Capitalization$1.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.82
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Read More
Esperion Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ESPR
CUSIPN/A
Phone734-887-3903

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$148.36 million
Book Value$0.73 per share

Profitability

Net Income$-97,170,000.00

Miscellaneous

Employees76
Market Cap$1.04 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$37.52
+1.47 (+4.08 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

How has Esperion Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ESPR shares have decreased by 12.6% and is now trading at $37.52.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Esperion Therapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Esperion Therapeutics
.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Esperion Therapeutics
.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics Inc (NASDAQ:ESPR) released its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported $4.32 earnings per share for the quarter, beating the consensus estimate of $2.13 by $2.19. The biopharmaceutical company had revenue of $212.24 million for the quarter, compared to analysts' expectations of $147.97 million. Esperion Therapeutics had a negative net margin of 38.86% and a negative return on equity of 271.49%. The company's quarterly revenue was up 21557.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.01) EPS.
View Esperion Therapeutics' earnings history
.

What price target have analysts set for ESPR?

12 equities research analysts have issued 12 month price objectives for Esperion Therapeutics' stock. Their forecasts range from $42.00 to $191.00. On average, they expect Esperion Therapeutics' stock price to reach $81.75 in the next year. This suggests a possible upside of 117.9% from the stock's current price.
View analysts' price targets for Esperion Therapeutics
.

Who are some of Esperion Therapeutics' key competitors?

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include Alon USA Partners (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), Gilead Sciences (GILD), Ship Finance International (SFL), Alibaba Group (BABA), BioMarin Pharmaceutical (bmrn) and Boeing (BA).

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the following people:
  • Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 58)
  • Dr. Narendra D. Lalwani, Exec. VP of R&D (Age 66)
  • Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 37)
  • Mr. Alexander Duke Schwartz, Sr. Director of Investor Relations
  • Ms. Marianne Andreach, Sr. VP

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bellevue Group AG (19.06%), Vanguard Group Inc. (8.49%), Wasatch Advisors Inc. (4.51%), Platinum Investment Management Ltd. (3.08%), Avidity Partners Management LP (2.01%) and Rhenman & Partners Asset Management AB (1.54%). Company insiders that own Esperion Therapeutics stock include Boxer Capital, Llc, Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends for Esperion Therapeutics
.

Which major investors are selling Esperion Therapeutics stock?

ESPR stock was sold by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Rhenman & Partners Asset Management AB, Vanguard Group Inc., Candriam Luxembourg S.C.A., FMR LLC, FMR LLC, Nicholas Investment Partners LP, and SG Americas Securities LLC.
View insider buying and selling activity for Esperion Therapeutics
.

Which major investors are buying Esperion Therapeutics stock?

ESPR stock was acquired by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Wasatch Advisors Inc., Bellevue Group AG, Bamco Inc. NY, Goldman Sachs Group Inc., Platinum Investment Management Ltd., Sei Investments Co., and Mutual of America Capital Management LLC. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech, and Timothy M Mayleben.
View insider buying and selling activity for Esperion Therapeutics
.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $37.52.

How big of a company is Esperion Therapeutics?

Esperion Therapeutics has a market capitalization of $1.04 billion and generates $148.36 million in revenue each year. The biopharmaceutical company earns $-97,170,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is www.esperion.com.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.